You are here

AI-Enabled Test for Kidney Disease Gets Breakthrough Device Designation

FDA Gives Priority Regulatory Review of Diagnostic for Fast-Progressing Kidney Disease

Renalytix AI plc has received an FDA Breakthrough Device Designation for KidneyIntelXTM, its main diagnostic test for kidney disease.

The device is designed to diagnose and improve clinical management of patients with type-2 diabetes with fast-progressing kidney disease. Using machine-learning algorithms, KidneyIntelX will assess the combination of predictive blood-based biomarkers, including sTNFR1, sTNFR2 and KIM1, with electronic health record information, to identify progressive kidney disease.

Globally, kidney disease is recognized as a public health epidemic affecting more than 850 million people, making its early detection and intervention crucial. The annual cost of chronic and end-stage kidney disease to the U.S. health care system is estimated to be $114 billion. Each day, 13 patients die in the U.S. while waiting for a kidney transplant.

Source: Renalytix AI plc, May 2, 2019

Recent Headlines

Safety concerns include liver injury and interactions with other drugs
No tobacco product is safe, says the lung heath group
Discovery seen as possibly leading to new anti-TB drugs
Study points to permanent hair dye and straighteners
How malaria parasites evade first-line drugs
A new way to fight staph infections
Score could help prevent misuse among cancer patients